SS Innovations International, Inc.
No SEC Form 4 filings for $SSII in the last 30 days.
See all $SSII insider activity →SS Innovations International reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, with 244 systems installed, up 45% from 2025. The company is expanding into 12 countries and pursuing U.S. FDA and EU CE clearances. Cumulative procedures reached 14,503.
SS Innovations (SSII) reported $42.5M revenue for 2025, up from $20.6M in 2024, with a 46.0% gross margin. The company also highlighted rapid adoption with 244 systems installed and 14,503 cumulative surgeries. Regulatory milestones include EU CE anticipated in Q4 2026 and US FDA market clearance in Q1 2027.
SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 21, 2026, Sarah Romano is no longer serving as Chief Financial Officer of the Company. Ms. Romano's depart
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SSII (SS Innovations International, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent SSII coverage spans corporate actions, technology and financial news.
The disclosed telesurgery volume and installed-base growth support a positive read-through for regulatory and commercial traction, but near-term valuation impact depends on FDA/CE clearance timing.
Revenue guidance and regulatory timeline suggest strong growth potential.
Executive turnover may affect investor perception and short‑term stock volatility.
The 8-K provides fresh quarterly financials plus forward-looking FDA 510(k) timing (by end of Q1 2027) and EU CE-mark target (end of 2026).
The article is a promotional update on installed base growth and ongoing regulatory work, which can support longer-term adoption expectations but lacks a discrete approval or filing milestone.
AlphAI scores every news story that mentions SSII with an AI model for sentiment and relevance, and aggregates insider trades from SS Innovations International, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SS Innovations International reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, with 244 systems installed, up 45% from 2025. The company is expanding into 12 countries and pursuing U.S. FDA and EU CE clearances. Cumulative procedures reached 14,503.
4 min readSS Innovations (SSII) reported $42.5M revenue for 2025, up from $20.6M in 2024, with a 46.0% gross margin. The company also highlighted rapid adoption with 244 systems installed and 14,503 cumulative surgeries. Regulatory milestones include EU CE anticipated in Q4 2026 and US FDA market clearance in Q1 2027.
1 min readSS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 21, 2026, Sarah Romano is no longer serving as Chief Financial Officer of the Company. Ms. Romano's depart
1 min readSS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SS Innovations Reports Second Quarter 2026 Financial Results Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales FORT LAUDERDALE, FLA – August 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq:
6 min readSS Innovations International (SSII) says it is expanding globally in surgical robotics using its SSi Mantra platform. The company reports 200+ systems installed worldwide and 12,000+ procedures across 170+ indications. It continues pursuing U.S. FDA clearance and European approvals while building its international installed base.
2 min readSS Innovations International, Inc. (Nasdaq: SSII) appointed Sarah M. Romano as Chief Financial Officer, effective Aug. 3, 2026. The company said she will support global expansion and the pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system. Romano previously served as CFO of Vicarious Surgical and other life sciences firms.
3 min readSS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029760101ex10-1.htm EMPLOYMENT AGREEMENT BETWEEN SS INNOVATIONS INTERNATIONAL, INC. AND SARAH M. ROMANO Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “ Agreement ”) is made and entered into as of June 22, 2026, by and between SS
4 min readSS Innovations International (NASDAQ: SSII) said its subsidiary SSICRS graduated its first class of 33 participants from seven countries from a five-day Cardiac Robotic Surgery Training course. Training used the SSi Mantra robotic system and covered procedures including endoscopic CABG, atrial septal defect repair, and mitral valve surgery. The company plans additional condensed multi-specialty courses.
2 min readSS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ea029521301ex1-1.htm ATM SALES AGREEMENT, DATED JUNE 18, 2026, BY AND BETWEEN SS INNOVATIONS INTERNATIONAL, INC AND VIRTU AMERICAS LLC Exhibit 1.1 EXECUTION VERSION SS INNOVATIONS INTERNATIONAL, INC. Common Stock (par value $0.0001 per share) ATM Sales Agreement June 18,
2 min readSS Innovations International (Nasdaq: SSII) said it completed a robot-assisted cardiac telesurgery between Georgetown, Guyana and Indore, India using its SSi Mantra system, covering about 12,500 miles (20,000 km) of fiber distance. The company said 22 cardiac telesurgeries have been done with SSi Mantra, and 173 telesurgeries globally; Guyana GA-FDD approved the system in May 2026.
4 min read
